DK3139925T3 - Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser - Google Patents

Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser Download PDF

Info

Publication number
DK3139925T3
DK3139925T3 DK15724438.5T DK15724438T DK3139925T3 DK 3139925 T3 DK3139925 T3 DK 3139925T3 DK 15724438 T DK15724438 T DK 15724438T DK 3139925 T3 DK3139925 T3 DK 3139925T3
Authority
DK
Denmark
Prior art keywords
valbenazine
treatment
movement disorders
dosing system
hyperkinetic movement
Prior art date
Application number
DK15724438.5T
Other languages
English (en)
Inventor
Christopher F O'brien
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of DK3139925T3 publication Critical patent/DK3139925T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK15724438.5T 2014-05-06 2015-05-06 Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser DK3139925T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Publications (1)

Publication Number Publication Date
DK3139925T3 true DK3139925T3 (da) 2021-12-20

Family

ID=53264772

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21178882.3T DK3936130T3 (da) 2014-05-06 2015-05-06 Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser
DK15724438.5T DK3139925T3 (da) 2014-05-06 2015-05-06 Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK21178882.3T DK3936130T3 (da) 2014-05-06 2015-05-06 Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser

Country Status (23)

Country Link
US (3) US20170071932A1 (da)
EP (3) EP4389227A2 (da)
JP (3) JP6635945B2 (da)
KR (4) KR20160147044A (da)
CN (3) CN112741835A (da)
AU (1) AU2015256012B2 (da)
CA (1) CA2947736C (da)
CY (1) CY1125058T1 (da)
DK (2) DK3936130T3 (da)
ES (1) ES2904526T3 (da)
FI (1) FI3936130T3 (da)
HR (2) HRP20220025T1 (da)
HU (1) HUE057839T2 (da)
IL (1) IL248745B (da)
LT (2) LT3139925T (da)
MX (1) MX2016014429A (da)
NZ (1) NZ725826A (da)
PL (2) PL3936130T3 (da)
PT (2) PT3936130T (da)
RS (2) RS65359B1 (da)
RU (1) RU2753740C2 (da)
SI (2) SI3936130T1 (da)
WO (1) WO2015171802A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065406T2 (hu) * 2015-10-30 2024-05-28 Neurocrine Biosciences Inc Valbenazin-dihidroklorid sók és polimorfjaik
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
WO2018001335A1 (zh) * 2016-06-29 2018-01-04 苏州科睿思制药有限公司 Nbi-98854的晶型及其制备方法和用途
WO2018102673A1 (en) * 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
KR20230038601A (ko) 2017-01-27 2023-03-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 ｖｍａｔ2 억제제의 투여 방법
US10954235B2 (en) 2017-02-27 2021-03-23 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
RU2022104034A (ru) * 2017-04-01 2022-03-05 Адептио Фармасьютикалз Лимитед Фармацевтические композиции
WO2018178233A1 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20200179352A1 (en) * 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US20200230127A1 (en) * 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EP3706748A4 (en) * 2017-11-08 2021-08-11 Foresee Pharmaceuticals Co., Ltd. ESTER OF DIHYDROTETRABENAZINE
KR102447769B1 (ko) 2017-12-26 2022-09-26 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 발베나진 토실산염의 결정형 및 그 제조 방법 및 용도
MX2020011269A (es) * 2018-04-25 2020-12-11 Shinkei Therapeutics Llc Dispositivo de administración transdérmica de tetrabenazina.
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
KR20210021006A (ko) 2018-06-14 2021-02-24 뉴로크린 바이오사이언시즈 인코퍼레이티드 Vmat2 억제제 화합물, 조성물 및 그와 관련된 방법
EP3836926A4 (en) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
WO2020070236A1 (en) 2018-10-04 2020-04-09 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
MX2021013132A (es) * 2019-05-09 2021-11-25 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2).
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2668689C (en) * 2006-11-08 2015-12-29 Neurocrine Biosciences Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
WO2008060451A2 (en) * 2006-11-09 2008-05-22 New York University Graded glass/zirconia/glass structures for damage resistant ceramic dental and orthopedic prostheses
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US8524733B2 (en) 2008-09-18 2013-09-03 Auspex Pharmaceuticals Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP2464340A2 (en) * 2009-08-12 2012-06-20 Valeant International (Barbados) SRL Pharmaceutical compositions with tetrabenazine
US20120003330A1 (en) * 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
BR112015005894B1 (pt) * 2012-09-18 2022-03-29 Auspex Pharmaceuticals, Inc Composto, composição farmacêutica, método para tratar um distúrbio mediado por vmat2 e formulação farmacêutica de liberação prolongada
NZ760790A (en) * 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Also Published As

Publication number Publication date
HRP20220025T1 (hr) 2022-04-01
PT3936130T (pt) 2024-04-17
CN112741835A (zh) 2021-05-04
RU2016147523A3 (da) 2018-12-28
JP2017514850A (ja) 2017-06-08
JP2021191799A (ja) 2021-12-16
US20170071932A1 (en) 2017-03-16
RU2016147523A (ru) 2018-06-08
EP3936130B1 (en) 2024-02-14
KR20240011255A (ko) 2024-01-25
CY1125058T1 (el) 2023-06-09
LT3936130T (lt) 2024-04-25
DK3936130T3 (da) 2024-03-25
EP4389227A2 (en) 2024-06-26
EP3936130A1 (en) 2022-01-12
HUE057839T2 (hu) 2022-06-28
SI3139925T1 (sl) 2022-04-29
IL248745B (en) 2022-07-01
JP2019218407A (ja) 2019-12-26
EP3139925A1 (en) 2017-03-15
SI3936130T1 (sl) 2024-05-31
EP3139925B1 (en) 2021-12-01
PL3936130T3 (pl) 2024-06-10
WO2015171802A1 (en) 2015-11-12
RS62782B1 (sr) 2022-01-31
PL3139925T3 (pl) 2022-03-21
JP6635945B2 (ja) 2020-01-29
RS65359B1 (sr) 2024-04-30
CA2947736C (en) 2023-04-18
KR20160147044A (ko) 2016-12-21
CN106456629A (zh) 2017-02-22
KR20220140647A (ko) 2022-10-18
LT3139925T (lt) 2022-01-25
PT3139925T (pt) 2022-01-26
CN112741836A (zh) 2021-05-04
AU2015256012B2 (en) 2020-07-23
US20210196702A1 (en) 2021-07-01
CA2947736A1 (en) 2015-11-12
MX2016014429A (es) 2017-04-06
HRP20240459T1 (hr) 2024-06-21
KR20200133003A (ko) 2020-11-25
IL248745A0 (en) 2017-01-31
RU2753740C2 (ru) 2021-08-23
US20200101063A1 (en) 2020-04-02
FI3936130T3 (fi) 2024-04-23
NZ725826A (en) 2023-05-26
AU2015256012A1 (en) 2016-11-24
ES2904526T3 (es) 2022-04-05

Similar Documents

Publication Publication Date Title
DK3139925T3 (da) Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3139982T3 (da) Forstøver
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK3172227T3 (da) Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3265421T3 (da) Doseringssystem
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3195160T3 (da) Computerstyret doseringssystem
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3204398T3 (da) Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3129122T3 (da) Rensningssystem til lakpartikler
DK3171701T3 (da) Infusionsanlæg
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser